Cellectis S.A.

Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.

CLLS | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 8 RUE DE LA CROIX JARRY, 0 PARIS, LLE-DE-FRANCE
Website:: https://www.cellectis.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. The company leverages its proprietary gene-editing technology, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Cellectis focuses on creating allogeneic, or "off-the-shelf," CAR T-cell product candidates from healthy donor cells. This approach aims to provide broadly available and scalable treatments for a large number of patients, in contrast to personalized autologous therapies. The company's technology is designed to solve key challenges in allogeneic cell therapy, including Graft-versus-Host Disease (GvHD) and host-versus-graft rejection. Cellectis maintains a strong intellectual property portfolio and collaborates with global strategic partners to advance its therapeutic pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectis S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectis S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Cellectis S.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
cbdMD, Inc. Produces & distributes lab-tested CBD wellness products for people and pets.	United States of America	YCBD
CDT Equity Inc. Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.	United States of America	CDT
CELADON PHARMACEUTICALS PLC Vertically integrated pharma developing cannabis medicines for chronic pain.	United Kingdom	CEL
Celcuity Inc. Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.	United States of America	CELC
Celemics, Inc. Develops custom NGS panels and bioinformatics for research and clinical diagnostics.	South Korea	331920
Cellbion Co., Ltd Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.	South Korea	308430
CELL BIOTECH CO ., LTD A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.	South Korea	049960
Celldex Therapeutics, Inc. Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.	United States of America	CLDX
Cellectar Biosciences, Inc. Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.	United States of America	CLRB
Cellectis Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.	France	ALCLS